| P2093 | author name string | Jaishri O Blakeley | |
| | Scott R Plotkin | |
| P2860 | cites work | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus | Q24300770 |
| | The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes | Q24309158 |
| | Diversity and specialization of mammalian SWI/SNF complexes | Q24322918 |
| | The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins | Q24324729 |
| | Mutation and cancer: statistical study of retinoblastoma | Q24618185 |
| | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| | Malignant peripheral nerve sheath tumours in neurofibromatosis 1 | Q24679356 |
| | A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor | Q27003534 |
| | Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. | Q27853117 |
| | The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis | Q28116515 |
| | Diagnostic criteria for schwannomatosis | Q28256490 |
| | Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas | Q28260652 |
| | The molecular pathology of cancer | Q28278125 |
| | Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival | Q28283076 |
| | SWI/SNF chromatin remodeling complex is obligatory for BMP2-induced, Runx2-dependent skeletal gene expression that controls osteoblast differentiation | Q28587715 |
| | Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 | Q28594951 |
| | The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 | Q28609120 |
| | Cooperation between complexes that regulate chromatin structure and transcription | Q29614769 |
| | Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis | Q60145699 |
| | Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1 | Q60696729 |
| | National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987 | Q67261485 |
| | Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma | Q73326046 |
| | Novel mutations of neurofibromatosis type 1 gene in small cell lung cancers | Q73362762 |
| | Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas | Q80350602 |
| | Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis | Q81684801 |
| | Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions | Q83372844 |
| | Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2 | Q86444215 |
| | Ketotifen suppression of NF1 neurofibroma growth over 30 years | Q87309079 |
| | Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 | Q30387415 |
| | Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. | Q30388655 |
| | Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors | Q30391370 |
| | Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis | Q30394068 |
| | CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. | Q30402063 |
| | Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. | Q30406342 |
| | Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. | Q30422022 |
| | Recommendations for imaging tumor response in neurofibromatosis clinical trials | Q30425757 |
| | Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. | Q30425761 |
| | Optimizing biologically targeted clinical trials for neurofibromatosis. | Q30438898 |
| | Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. | Q30450038 |
| | AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas | Q30464276 |
| | Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature | Q30493204 |
| | Gamma knife stereotactic radiosurgery for unilateral acoustic neuromas | Q30495461 |
| | The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway | Q30606515 |
| | Phase II study of carboplatin in children with progressive low-grade gliomas | Q33343014 |
| | Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. | Q33561323 |
| | Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. | Q33711291 |
| | Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders | Q33723849 |
| | Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. | Q33723856 |
| | SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis | Q33800041 |
| | Quantitative analysis of mammalian GIRK2 channel regulation by G proteins, the signaling lipid PIP2 and Na+ in a reconstituted system | Q34055491 |
| | Malignancy in neurofibromatosis type 1. | Q34100904 |
| | Meningiomas and neurofibromatosis. | Q34131583 |
| | A mutant allele of the Swi/Snf member BAF250a determines the pool size of fetal liver hemopoietic stem cell populations | Q34162999 |
| | Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship | Q34193347 |
| | Malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1 | Q34275638 |
| | Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients | Q34288675 |
| | What is the real incidence of vestibular schwannoma? | Q34299160 |
| | Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. | Q34342958 |
| | Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought | Q34392256 |
| | Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas | Q34393793 |
| | The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. | Q34458646 |
| | E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. | Q37616951 |
| | Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | Q37699439 |
| | Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. | Q37716733 |
| | Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. | Q37737382 |
| | SWI/SNF complexes, chromatin remodeling and skeletal myogenesis: it's time to exchange! | Q37765666 |
| | The Diagnostic and Clinical Significance of Café-au-lait Macules | Q37796203 |
| | Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium | Q38088574 |
| | Li-Fraumeni syndrome: cancer risk assessment and clinical management | Q38197030 |
| | Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types | Q39377991 |
| | Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. | Q39512836 |
| | Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. | Q39555847 |
| | Variable expressivity of neurofibromatosis-1 in identical twins | Q39611043 |
| | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Q39692148 |
| | The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors | Q40070769 |
| | Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. | Q40181731 |
| | Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. | Q41342455 |
| | Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations | Q42548316 |
| | A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. | Q42609349 |
| | Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway | Q42804824 |
| | Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients | Q43074091 |
| | A negative feedback signaling network underlies oncogene-induced senescence | Q43116108 |
| | Neurofibromatosis 2, radiosurgery and malignant nervous system tumours | Q43216302 |
| | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. | Q44276749 |
| | Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri | Q44718402 |
| | Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity | Q45349874 |
| | Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients | Q46082677 |
| | Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. | Q46138119 |
| | Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects | Q46768033 |
| | The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling | Q47071805 |
| | NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. | Q47306235 |
| | Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2. | Q47642138 |
| | Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene | Q48056312 |
| | Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | Q48079152 |
| | Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients | Q48428414 |
| | Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab | Q48769865 |
| | Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy | Q48784484 |
| | Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. | Q48872525 |
| | Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab | Q48872539 |
| | Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients | Q48961990 |
| | Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. | Q50357611 |
| | Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. | Q50425679 |
| | Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium | Q50443009 |
| | Radiosurgery for type II neurofibromatosis | Q50449685 |
| | Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. | Q50450347 |
| | The neuroimaging and clinical spectrum of neurofibromatosis 2. | Q50514920 |
| | Increasing annual incidence of vestibular schwannoma and age at diagnosis. | Q50749724 |
| | Pulmonary hypertension in patients with neurofibromatosis type I. | Q51472493 |
| | Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. | Q52068358 |
| | Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. | Q53116195 |
| | Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. | Q55463289 |
| | Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. | Q55470115 |
| | Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. | Q55481914 |
| | SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors | Q57266497 |
| | Genetic testing and screening of individuals at risk of NF2 | Q57266536 |
| | Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis | Q57266550 |
| | Life expectancy in hereditary cancer predisposing diseases: an observational study | Q57266560 |
| | Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis | Q57266581 |
| | SMARCB1 mutations are not a common cause of multiple meningiomas | Q57266630 |
| | Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service | Q57266646 |
| | Increasing the specificity of diagnostic criteria for schwannomatosis | Q57266735 |
| | Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4DCAF1 to Suppress Oncogenic Gene Expression | Q57275665 |
| | Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas | Q57386667 |
| | Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation | Q57737866 |
| | Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset | Q34467227 |
| | Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas | Q34555308 |
| | Clinical response to bevacizumab in schwannomatosis | Q34591266 |
| | Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. | Q34739729 |
| | The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | Q34741372 |
| | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice | Q34791274 |
| | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice | Q34799331 |
| | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Q34980977 |
| | Conclusions and future directions for the REiNS International Collaboration. | Q35046441 |
| | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development | Q35133489 |
| | Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. | Q35652582 |
| | Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers | Q35657827 |
| | Expanding the mutational spectrum of LZTR1 in schwannomatosis | Q35722195 |
| | Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. | Q35788825 |
| | Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth | Q35788976 |
| | A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma | Q35791274 |
| | Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis | Q36010097 |
| | Contact-dependent inhibition of EGFR signaling by Nf2/Merlin | Q36118464 |
| | Management of the patient and family with neurofibromatosis 2: a consensus conference statement | Q36251326 |
| | Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes | Q36254710 |
| | Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. | Q36268076 |
| | Clinical features of schwannomatosis: a retrospective analysis of 87 patients | Q36349611 |
| | The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level | Q36377651 |
| | Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. | Q36395077 |
| | Neurofibromatosis type 1: new insights into neurocognitive issues | Q36415807 |
| | Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? | Q36483309 |
| | A prospective study of neurofibromatosis type 1 cancer incidence in the UK. | Q36612055 |
| | Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. | Q36771546 |
| | Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression | Q36960893 |
| | Magic but treatable? Tumours due to loss of merlin. | Q36972789 |
| | Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations | Q36982106 |
| | Gliomas in patients with neurofibromatosis type 1. | Q37432196 |
| | ATP-dependent chromatin remodeling in neural development. | Q37482388 |
| | Functional outcome measures for NF1-associated optic pathway glioma clinical trials | Q37536287 |
| P433 | issue | 5 | |
| P304 | page(s) | 624-638 | |
| P577 | publication date | 2016-02-06 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis | |
| P478 | volume | 18 | |